Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taladegib with Chemoradiation for Esophageal Adenocarcinoma
NCT02530437Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of taladegib in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2017; status: terminated.
02
Drugs
taladegib
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02530437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530437.